Furosemide versus placebo for fluid overload in intensive care patients—The randomised GODIF trial second version: Statistical analysis plan

Abstract

AbstractBackgroundFluid overload is associated with increased mortality in intensive care unit (ICU) patients. The GODIF trial aims to assess the benefits and harms of fluid removal with furosemide versus placebo in stable adult patients with moderate to severe fluid overload in the ICU. This article describes the detailed statistical analysis plan for the primary results of the second version of the GODIF trial.MethodsThe GODIF trial is an international, multi‐centre, randomised, stratified, blinded, parallel‐group, pragmatic clinical trial, allocating 1000 adult ICU patients with moderate to severe fluid overload 1:1 to furosemide versus placebo. The primary outcome is days alive and out of hospital within 90 days post‐randomisation. With a power of 90% and an alpha level of 5%, we may reject or detect an improvement of 8%. The primary analyses of all outcomes will be performed in the intention‐to‐treat population. For the primary outcome, the Kryger Jensen and Lange method will be used to compare the two treatment groups adjusted for stratification variables supplemented with sensitivity analyses in the per‐protocol population and with further adjustments for prognostic variables. Secondary outcomes will be analysed with multiple linear regressions, logistic regressions or the Kryger Jensen and Lange method as suitable with adjustment for stratification variables.ConclusionThe GODIF trial data will increase the certainty about the effects of fluid removal using furosemide in adult ICU patients with fluid overload.Trial Registrations: EudraCT identifier: 2019‐004292‐40 and ClinicalTrials.org: NCT04180397.